Results 11 to 20 of about 50,518 (225)

Pneumococcal whole-cell and protein-based vaccines: changing the paradigm

Expert Review of Vaccines, 2017
Introduction: Epidemiologic evaluations of Streptococcus pneumoniae nasopharyngeal (NP) colonization and pneumococcal disease suggest that newer serotypes in future formulations of pneumococcal conjugate vaccines (PCVs) are needed and there may need to ...
Michael E. Pichichero
doaj   +2 more sources

Efficacy and effectiveness of extended-valency pneumococcal conjugate vaccines [PDF]

Korean Journal of Pediatrics, 2014
The 7-valent pneumococcal protein conjugate vaccine (PCV7) has been shown to be highly efficacious against invasive pneumococcal diseases and effective against pneumonia and in reducing otitis media. The introduction of PCV7 has resulted in major changes
Hyunju Lee, Eun Hwa Choi, Hoan Jong Lee
doaj   +1 more source

Pneumococcal Choline-Binding Proteins Involved in Virulence as Vaccine Candidates

Vaccines, 2021
Streptococcus pneumoniae is a pathogen responsible for millions of deaths worldwide. Currently, the available vaccines for the prevention of S.
Julio Sempere, Mirella Llamosí, Idoia del Río Menéndez, Beatriz López Ruiz, Mirian Domenech, Fernando González-Camacho   +5 more
doaj   +1 more source

The COVID-19 pandemic increased the demand for pneumococcal vaccination in Japan

Human Vaccines & Immunotherapeutics, 2021
Although routine vaccinations in children decreased during the coronavirus disease 2019 (COVID-19) pandemic, pneumococcal vaccine coverage in older adults has remained unknown.
Akira Komori, Hirotake Mori, Toshio Naito   +2 more
doaj   +1 more source

Adult pneumococcal vaccination – new opportunities

Family Medicine & Primary Care Review, 2023
Pneumococcal infections (Streptococcus pneumoniae) remain a significant epidemiological problem globally. Although an invasive pneumo-coccal disease (IPD), which includes meningitis, sepsis and pneumonia with bacteremia, is the most severe form of ...
ERNEST KUCHAR, JOANNA CHOROSTOWSKA-WYNIMKO, LESZEK CZUPRYNIAK, ANDRZEJ FAL, ROBERT FLISIAK, ARTUR MAMCARZ, ANETA NITSCH-OSUCH, ANNA SKOCZYŃSKA, MARCIN STAJSZCZYK, JACEK WYSOCKI, MICHAŁ ABENDROT, DOMINIK GOLICKI, KATARZYNA JAŚKOWIAK, ADAM ANTCZAK   +13 more
doaj   +1 more source

Evaluation of a phased pneumococcal conjugate vaccine introduction in Mongolia using enhanced pneumonia surveillance and community carriage surveys: a study protocol for a prospective observational study and lessons learned

BMC Public Health, 2019
Background Streptococcus pneumoniae causes substantial morbidity and mortality among children. The introduction of pneumococcal conjugate vaccines (PCV) has the potential to dramatically reduce disease burden.
S. F. La Vincente, C. von Mollendorf, M. Ulziibayar, C. Satzke, L. Dashtseren, K. K. Fox, E. M. Dunne, C. D. Nguyen, J. de Campo, M. de Campo, H. Thomson, G. Surenkhand, S. Demberelsuren, S. Bujinlkham, L. A. H. Do, D. Narangerel, T. Cherian, T. Mungun, E. K. Mulholland   +18 more
doaj   +1 more source

30-Minute Highly Multiplexed VaxArray Immunoassay for Pneumococcal Vaccine Antigen Characterization

Vaccines, 2022
Pneumonia accounts for over 20% of deaths worldwide in children aged 1 to 5 years, disproportionately affecting lower- and middle-income countries.
Tianjing Hu, David F. Miller, Amber W. Taylor, Christine Riley, Caitlin McCormick, Keely N. Thomas, Rachel Y. Gao, Kathy L. Rowlen, Emilia B. Byrne, Pardeep Kumar, Soo Kyung Kim, Erica D. Dawson   +11 more
doaj   +1 more source

[Pneumococcal vaccine].

Annali di igiene : medicina preventiva e di comunita, 2001
Gli autori descrivono le caratteristiche del vaccino anti-pneumococcico polisaccaridi, ponendo una particolare attenzione alla sua efficacia e tollerabilità nella popolazione anziana.
D'ALESSANDRO, Daniela, Y. Kodra
openaire   +6 more sources

Possible Cross-Reactivity between SARS-CoV-2 Proteins, CRM197 and Proteins in Pneumococcal Vaccines May Protect Against Symptomatic SARS-CoV-2 Disease and Death

Vaccines, 2020
Various studies indicate that vaccination, especially with pneumococcal vaccines, protects against symptomatic cases of SARS-CoV-2 infection and death.
Robert Root-Bernstein
doaj   +1 more source

Impact of Pneumococcal Conjugate Vaccines on Pneumonia Hospitalizations in High- and Low-Income Subpopulations in Brazil. [PDF]

, 2017
BackgroundPneumococcal conjugate vaccines (PCVs) are being used worldwide. A key question is whether the impact of PCVs on pneumonia is similar in low- and high-income populations.
Kürüm, Esra, Lustig, Roger, Schuck-Paim, Cynthia, Shioda, Kayoko, Simonsen, Lone, Taylor, Robert J, Warren, Joshua L, Weinberger, Daniel M   +7 more
core   +2 more sources